Selinexor

Last Updated: 02/24/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 597 publications

Retraction Note: Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.

Retraction Note: Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.

Journal: Scientific reports
Published: December 15, 2025

Systematic elucidation and pharmacologic targeting on non-oncogene dependencies in imatinib-resistant gastrointestinal stromal tumor.

Systematic elucidation and pharmacologic targeting on non-oncogene dependencies in imatinib-resistant gastrointestinal stromal tumor.

Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025

Exportin 1 as a Therapeutic Target to Overcome Drug Resistance in Lung Cancer.

Exportin 1 as a Therapeutic Target to Overcome Drug Resistance in Lung Cancer.

Journal: Cells
Published: November 14, 2025

Efficacy and Safety of Selinexor Combined with VRD in Newly Diagnosed Multiple Myeloma with EMD: A Phase 2 Trial.

Efficacy and Safety of Selinexor Combined with VRD in Newly Diagnosed Multiple Myeloma with EMD: A Phase 2 Trial.

Journal: Blood advances
Published: October 29, 2025

Therapeutic Potential of Exportin 1 and Aurora Kinase A Inhibition in Multiple Myeloma Cells.

Therapeutic Potential of Exportin 1 and Aurora Kinase A Inhibition in Multiple Myeloma Cells.

Journal: Hematology reports
Published: October 22, 2025

Therapeutic horizons in targeting XPO1 with small inhibitor molecules: Recent achievements, synthetic strategies, opportunities, challenges, and future perspectives.

Therapeutic horizons in targeting XPO1 with small inhibitor molecules: Recent achievements, synthetic strategies, opportunities, challenges, and future perspectives.

Journal: Bioorganic chemistry
Published: October 08, 2025

Combined XPO1 Inhibition and Parthenolide Treatment Can Be Efficacious in Treating Triple-Negative Breast Cancer.

Combined XPO1 Inhibition and Parthenolide Treatment Can Be Efficacious in Treating Triple-Negative Breast Cancer.

Journal: International journal of molecular sciences
Published: October 03, 2025

SOHO State of the Art Updates and Next Questions | Treatment of Myeloma Early Relapse: Non-CAR T Cell.

SOHO State of the Art Updates and Next Questions | Treatment of Myeloma Early Relapse: Non-CAR T Cell.

Journal: Clinical lymphoma, myeloma & leukemia
Published: September 24, 2025

Inhibition of CRM1 reverses hypoxia-driven chemoresistance in acute myeloid leukemia via overcoming HIF-1α-mediated lysosomal sequestration.

Inhibition of CRM1 reverses hypoxia-driven chemoresistance in acute myeloid leukemia via overcoming HIF-1α-mediated lysosomal sequestration.

Journal: Frontiers in immunology
Published: September 22, 2025

Functional precision approach in patients with very high risk acute lymphoblastic leukaemia in India: a single-centre cohort study.

Functional precision approach in patients with very high risk acute lymphoblastic leukaemia in India: a single-centre cohort study.

Journal: The Lancet regional health. Southeast Asia
Published: September 12, 2025

The Application Progress of Selinexor in the Treatment of Relapsed and Refractory Multiple Myeloma--Review

The Application Progress of Selinexor in the Treatment of Relapsed and Refractory Multiple Myeloma--Review

Journal: Zhongguo shi yan xue ye xue za zhi
Published: September 11, 2025

Selinexor combined with R-GDP as salvage therapy in relapsed/refractory diffuse large B-cell lymphoma.

Selinexor combined with R-GDP as salvage therapy in relapsed/refractory diffuse large B-cell lymphoma.

Journal: American journal of cancer research
Published: September 06, 2025
Showing 1-12 of 597

Last Updated: 02/24/2026